ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research
News Apr 16, 2012
ElexoPharm GmbH has announced the appointment of Dr. Chris J. van Koppen as Head of Research.
He will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.
Dr. van Koppen holds a Ph.D. in Pharmacology and brings extensive industry experience in drug discovery.
Before joining ElexoPharm in January 2012, he served as Leader of four lead optimization projects at Merck Sharp & Dohme, The Netherlands.
He was responsible for delivery of candidate drugs for preclinical development in endocrinological diseases.
Dr. van Koppen was also strongly involved in assay development, HTS, lead finding and proof-of-concept projects.
Before working at MSD, Dr. van Koppen was independent group leader at the Universitätsklinikum Essen and received his Habilitation in Pharmacology and Toxicology.
He has published almost 70 peer-reviewed research papers, including publications in high IF journals (J Biol Chem, Endocrinology, J Clin Endocrinol Metab, PNAS, Mol Pharmacol, Br J Pharmacol, Thorax, Pharmacol Ther, and EMBO Journal).
Axel Koch, Managing Director of ElexoPharm, said: “We are delighted to have such an experienced scientist as Head of Research. His expertise in successfully leading preclinical drug discovery projects will strongly advance our innovative portfolio.”
Dr. van Koppen adds: “I am thrilled to work in the dynamic team of ElexoPharm on highly innovative projects to design and develop drugs for the treatment of endocrinological, cardiovascular and neoplastic diseases.”
A breakthrough has been made in the fight against Alzheimer's disease - researchers have found a new way to target the toxic particles that destroy healthy brain cells. Academics have devised the first strategy to 'go after' the cause of the devastating disease, leading to hope that new drugs could be developed to treat dementia.READ MORE